Cytovance Biologics Enters cGMP Manufacturing Agreement With Selexys Pharmaceuticals
Cytovance Biologics,CMO of mammalian and microbial biologics, recently s announced that it has entered into a development and manufacturing agreement with Selexys Pharmaceuticals. Selexys, based out of Oklahoma City, is a clinical stage biopharmaceutical company that focuses on developing drugs that treat inflammatory diseases as well as cancer. The two companies are partnering for the manufacture of Selexys’ new investigational drug for Crohn’s Disease and Multiple Myeloma. The drug is called SELK2, and it is a humanized monoclonal antibody. Cytovance will be responsible for the process development, scaling up, and cGMP manufacturing of the SELK2 drug for a Phase I human clinical trial.
According to Scott Rollins, the President and CEO of Selexys, “With this agreement, Selexys continues its longstanding relationship with Cytovance. Cytovance has been an integral part in helping us advance our clinical trial programs. We look forward to working with the company’s team of professionals on this new product for the treatment of inflammatory diseases and cancer.”
Cytovance has been hard at work lately, increasing its facilities’ capacity and entering into manufacturing agreements with companies such as Pamlico and Precision Biologics. In January, Cytovance broke ground on a new facility that would expand the company’s manufacturing and GMP warehousing operations. The new facility will contain major additions, including a new 1000L Microbial Fermenter, an Automated Fill/Finish machine, and a 2500L stainless steel bioreactor.
In addition to this expansion, Cytovance and Precision Biologics announced the extension of their cGMP manufacturing agreement in March. Cytovance’s manufacturing agreement with Precision Biologics is to manufacture the company’s leading monoclonal antibody candidate, Ensituximab, which is intended for the treatment of pancreatic and colorectal cancers.
Cytovance’s manufacturing agreement with Pamlico Biopharma, which was made official in February of this year, is to manufacture a production cell line from the amino acid sequence of Streptococcus pneumonia for the purpose of phase I clinical trials.